Balyasny Asset Management
EWTX icon

Balyasny Asset Management’s Edgewise Therapeutics EWTX Stock Holding History

Balyasny Asset Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-151,905
Closed -$3.77M – 3069
2025
Q4 		$3.77M Buy
+151,905
New +$3.05M ﹤0.01% 1539
2025
Q2 		– Sell
-120,910
Closed -$2.66M – 2976
2025
Q1 		$2.66M Buy
120,910
+97,546
+418% +$2.56M ﹤0.01% 1567
2024
Q4 		$624K Buy
+23,364
New +$744K ﹤0.01% 2118
2024
Q3 		– Sell
-528,594
Closed -$9.52M – 2862
2024
Q2 		$9.52M Buy
+528,594
New +$9.22M 0.02% 908
2023
Q3 		– Sell
-20,660
Closed -$160K – 2386
2023
Q2 		$160K Buy
20,660
+5,420
+36% +$45.7K ﹤0.01% 2090
2023
Q1 		$102K Sell
15,240
-3,100
-17% -$28.7K ﹤0.01% 2313
2022
Q4 		$164K Buy
+18,340
New +$172K ﹤0.01% 2171

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Balyasny Asset Management's EWTX Position: Q1 2026 in Review

Balyasny Asset Management sold out of Edgewise Therapeutics (EWTX) in Q1 2026, closing a stake of 151,905 shares — an estimated $3.77M sold.

Balyasny Asset Management first reported a position in EWTX in Q4 2022 and held it in 7 quarters. The position peaked at $9.52M in Q2 2024. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

  • Balyasny Asset Management reported no remaining Edgewise Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 151,905 Edgewise Therapeutics shares in Q1 2026, an estimated $3.77M.
  • Balyasny Asset Management first reported a position in Edgewise Therapeutics in Q4 2022 and held it in 7 quarters.
  • Balyasny Asset Management's Edgewise Therapeutics position peaked at $9.52M in Q2 2024.
  • 214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.